Nasdaq:NEPH
NEPHROS INC
A biotechnology company pioneering microphysiological systems to revolutionize the treatment of chronic kidney disease through innovative tissue engineering models.
Key Metrics
Investment Thesis
Bull Case
Investors may be attracted to NEPHROS by its breakthrough nephron-on-a-chip technology which addresses the unmet medical need for kidney disease models, the potential for significant value creation upon successful commercialization or major licensing deals, and the clear trajectory of narrowing losses suggesting an eventual path to profitability.
Bear Case
Potential buyers should avoid the stock due to the alarming retained earnings deficit of $144.3M which suggests a high probability of dilution through equity issuance, the lack of consistent revenue growth in 2024 after a strong jump in 2023, and the fact that current operations are burning cash at a rate that threatens liquidity if major financing rounds are delayed.
About NEPHROS INC
NEPHROS Inc. develops and commercializes advanced regenerative medicine technologies focused on kidney disease, leveraging its proprietary nephron-on-a-chip platform to accelerate drug discovery and patient care.
Analysis
Management Discussion
While revenue grew from $10.0M in 2022 to $14.2M in 2023 and held steady in 2024, the company continues to report net losses narrowing from -$7.1M to a slight profit of $0.1M, indicating an improving bottom line despite heavy investments in research and development totaling over $900k.
Industry Overview
The medical device and biotechnology sector is experiencing rapid innovation in organ-on-a-chip technologies, aiming to replace traditional animal testing with more accurate human tissue models for drug safety evaluation.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $10.0M | $14.2M | $14.2M |
| Cost of Revenue | $5.2M | $5.8M | $5.4M |
| Gross Profit | $4.7M | $8.4M | $8.7M |
| Operating Expenses | $9.1M | $10.0M | $8.7M |
| Operating Income | $-4.3M | $-1.6M | $6.0K |
| R&D | $1.3M | $873.0K | $906.0K |
| G&A | $7.6M | $8.9M | $7.7M |
| Stock-Based Comp | $982.0K | $1.1M | $153.0K |
| D&A | $218.0K | $214.0K | $135.0K |
| Depreciation | $93.0K | $39.0K | $46.0K |
| Amortization | $42.0K | $42.0K | $32.0K |
| Other OpEx | $218.0K | $214.0K | $135.0K |
| Non-Operating Income | $58.0K | $18.0K | $83.0K |
| Interest Expense | $20.0K | $2.0K | — |
| Interest Income | $14.0K | $64.0K | $94.0K |
| Pre-Tax Income | $-4.3M | $-1.6M | $89.0K |
| Income Tax | $0 | $0 | $15.0K |
| Continuing Ops | $-4.3M | $-1.6M | $74.0K |
| Discontinued Ops | $-2.8M | $0 | $0 |
| Net Income | $-7.1M | $-1.6M | $74.0K |
| Minority Interest | $276.0K | $0 | $0 |
| Net to Common | $-7.4M | $-1.6M | $74.0K |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $8.3M | $8.4M | $8.3M |
| Cash & Equivalents | $3.6M | $4.3M | $3.8M |
| Accounts Receivable | $1.3M | $1.5M | $1.8M |
| Inventory | $3.2M | $2.5M | $2.6M |
| Prepaid Expenses | $188.0K | $132.0K | $142.0K |
| Other Current Assets | $0 | $0 | $0 |
| Long-Term Assets | $2.7M | $3.5M | $2.9M |
| PP&E (Net) | $116.0K | $152.0K | $161.0K |
| Goodwill | $759.0K | $759.0K | $759.0K |
| Operating Leases | $972.0K | $1.8M | $1.4M |
| Other LT Assets | $891.0K | $742.0K | $637.0K |
| Total Assets | $11.0M | $11.9M | $11.2M |
| Current Liabilities | $1.4M | $2.1M | $1.6M |
| Accounts Payable | $740.0K | $873.0K | $649.0K |
| Current Leases | $309.0K | $442.0K | $343.0K |
| Other Current Liab | $78.0K | $4.0K | $5.0K |
| Long-Term Liabilities | $706.0K | $1.4M | $1.1M |
| LT Operating Leases | $700.0K | $1.4M | $1.0M |
| Other LT Liab | $6.0K | $0 | $17.0K |
| Total Liabilities | $2.1M | $3.5M | $2.6M |
| Shareholders' Equity | $8.9M | $8.4M | $8.6M |
| Paid-In Capital | $148.4M | $152.8M | $152.9M |
| Retained Earnings | $-142.8M | $-144.4M | $-144.3M |
| Total L&E | $11.0M | $11.9M | $11.2M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-7.1M | $-1.6M | $74.0K |
| Non-Cash Adjustments | $6.3M | $1.6M | $-344.0K |
| Working Capital Changes | $-2.4M | $790.0K | $-222.0K |
| Cash from Operations | $-3.2M | $827.0K | $-492.0K |
| Capital Expenditures | $137.0K | $75.0K | $55.0K |
| Cash from Investing | $-137.0K | $-75.0K | $-50.0K |
| Cash from Financing | $34.0K | $-79.0K | $-5.0K |
| FX Effect | $-2.0K | $0 | $0 |
| Net Change in Cash | $-3.3M | $673.0K | $-547.0K |
| Beginning Cash | $7.0M | $3.6M | $4.3M |
| Ending Cash | $3.6M | $4.3M | $3.8M |
Frequently Asked Questions
How does NEPHROS INC make money?
The company's revenue primarily stems from contract research services utilizing its unique organ-on-a-chip technology, alongside potential licensing arrangements for its proprietary nephron models and related data analytics derived from long-term cell culture studies.
What are the main risks for NEPH?
The company faces significant financial risk due to a substantial accumulated deficit of $144.3M and negative operating cash flow of $492k in the latest period, relies heavily on external funding given its current cash balance of $3.8M, operates in a competitive biotech landscape with high regulatory hurdles for clinical translation, and is vulnerable to macroeconomic pressures affecting venture capital availability.
What is NEPH's competitive advantage?
NEPHROS possesses a robust intellectual property portfolio centered on the first-in-class nephron-on-a-chip platform, offers a differentiated value proposition by enabling long-term modeling of kidney disease progression not possible with traditional 2D cultures, and benefits from strategic partnerships that de-risk its high-cost R&D pipeline.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.